Impact News +++ Viridian Therapeutics prices $251M share offering (SeekingAlpha) +++ VIRIDIAN Aktie +3,25%

REPLIMUNE Aktie

>REPLIMUNE Aktienkurs

6.85 EUR -1.4% (Tradegate)

Ask: 7.1 EUR / 500 Stück

Bid: 6.7 EUR / 500 Stück

Tagesumsatz: 800 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REPLIMUNE Aktie über LYNX handeln

Intraday

1 Jahr

>REPLIMUNE Performance

1 Woche: +87,8%

1 Monat: +157,2%

3 Monate: -33,0%

6 Monate: +6,0%

1 Jahr: -32,4%

laufendes Jahr: -39,6%

>REPLIMUNE Aktie

Name:

REPLIMUNE GR. INC DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US76029N1063 / A2JQN1

Symbol/ Ticker:

7R8 (Frankfurt) / REPL (NASDAQ)

Kürzel:

FRA:7R8, ETR:7R8, 7R8:GR, NASDAQ:REPL

Index:

Webseite:

https://replimune.com/

Profil:

Replimune Group Inc. is a biotechnology company sp..
>Volltext..

Marktkapitalisierung:

601.61 Mio. EUR

Unternehmenswert:

323.11 Mio. EUR

Umsatz:

EBITDA:

-251.63 Mio. EUR

Nettogewinn:

-241.45 Mio. EUR

Gewinn je Aktie:

-2.91 EUR

Schulden:

65.77 Mio. EUR

Liquide Mittel:

83.9 Mio. EUR

Operativer Cashflow:

-189.65 Mio. EUR

Bargeldquote:

6.77

Umsatzwachstum:

Gewinnwachstum:

-15.81%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

REPLIMUNE

Letzte Datenerhebung:

22.10.25

>REPLIMUNE Kennzahlen

Aktien/ Unternehmen:

Aktien: 78.06 Mio. St.

Frei handelbar: 84.99%

Leerverk. Aktien: 22.91%

Rückkaufquote: -22.38%

Mitarbeiter: 479

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 25.27%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.95

PEG-Ratio: -2.53

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -55.79%

Eigenkaprendite: -73.44%

>REPLIMUNE Peer Group

Es sind 595 Aktien bekannt.

>REPLIMUNE Chart & Kurs - NASDAQ

>REPLIMUNE News

20.10.25 - 22:36	Why Replimune Stock Was Soaring Today (Fool)
	An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks....

20.10.25 - 16:42	WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday (Benzinga)
	read more...

20.10.25 - 15:06	Replimune soars 108% on BLA resubmission acceptance of melanoma asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.10.25 - 14:06	Replimune Soars After FDA Accepts Resubmitted Drug Application (Bloomberg)
	Replimune Group Inc. shares surged after US regulators accepted its resubmitted application for a skin cancer treatment, a sign that a previous denial could be overturned....

20.10.25 - 13:24	Replimune-Aktie explodiert um 60 %, nachdem die FDA den Zulassungsantrag für ein Melanom-Medikament akzeptiert (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

20.10.25 - 13:03	Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma (GlobeNewswire EN)
	Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026...

19.10.25 - 14:03

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 (GlobeNewswire EN)

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P)....

24.09.25 - 19:00	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
	Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch....

22.09.25 - 17:09	REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm (PR Newswire)
	NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22,......

22.09.25 - 11:36	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
	LOS ANGELES, Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

22.09.25 - 10:24	REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities......

20.09.25 - 16:57	Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman (PR Newswire)
	REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 20, 2025 On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the company announced......

19.09.25 - 22:48	Why Replimune Stock Was Tumbling Again Today (Fool)
	The biotech's recent meeting with FDA officials continued to resonate....

19.09.25 - 17:21	Replimune cut to Underweight at J.P. Morgan on further headline risk (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.09.25 - 01:24	Why Replimune Stock Plummeted by Almost 40% Today (Fool)
	The fate of a once-promising cancer treatment now looks uncertain at best....

19.09.25 - 00:33	Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025......

18.09.25 - 22:42	Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman (PR Newswire)
	REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the......

18.09.25 - 16:01	Replimune provides update on FDA meeting (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.09.25 - 15:18

Replimune Provides Update Following Type A Meeting with FDA (GlobeNewswire EN)

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete response letter (CRL) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma....

18.09.25 - 11:51	Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL (PR Newswire)
	LOS ANGELES, Sept. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer auf jede Feder siehet, wird langsam ein Bette zusammenbringen. - Sprichwort Deutschland

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram